Holen Sie sich die Stockscreener-App
71.49
3.46%
2.39
Schlusskurs vom Vortag:
$69.10
Offen:
$69.1
24-Stunden-Volumen:
350.65K
Relative Volume:
0.29
Marktkapitalisierung:
$3.70B
Einnahmen:
$412.82M
Nettoeinkommen (Verlust:
$-8.19M
KGV:
-463.92
EPS:
-0.1541
Netto-Cashflow:
$64.17M
1W Leistung:
+3.31%
1M Leistung:
+12.26%
6M Leistung:
+227.19%
1J Leistung:
+392.69%
1-Tages-Spanne:
$68.60
$71.69
1-Wochen-Bereich:
$66.84
$72.71
52-Wochen-Spanne:
$14.22
$72.71
Caredx Inc Stock (CDNA) Company Profile
Firmenname
Caredx Inc
Sektor
Branche
Telefon
415-287-2300
Adresse
8000 MARINA BLVD, BRISBANE, CA
Compare CDNA vs TMO, DHR, NTRA, A, WAT
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CDNA
Caredx Inc
|
71.49 | 3.70B | 412.82M | -8.19M | 64.17M | -0.1541 |
TMO
Thermo Fisher Scientific Inc
|
695.55 | 257.18B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
232.23 | 163.25B | 24.78B | 3.68B | 5.29B | 5.1743 |
NTRA
Natera Inc
|
412.96 | 59.53B | 2.50B | -226.32M | 71.51M | -1.6412 |
A
Agilent Technologies Inc
|
178.05 | 50.20B | 7.23B | 1.41B | 1.09B | 4.979 |
WAT
Waters Corp
|
464.00 | 45.59B | 3.77B | 449.25M | 240.68M | 7.8556 |
Caredx Inc Stock (CDNA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-09-02 | Eingeleitet | Canaccord Genuity | Buy |
| 2026-08-03 | Hochstufung | Craig Hallum | Hold → Buy |
| 2026-01-06 | Herabstufung | Craig Hallum | Buy → Hold |
| 2025-08-26 | Eingeleitet | William Blair | Mkt Perform |
| 2025-01-15 | Hochstufung | Wells Fargo | Underweight → Equal Weight |
| 2024-08-28 | Eingeleitet | Wells Fargo | Underweight |
| 2024-08-19 | Hochstufung | BTIG Research | Neutral → Buy |
| 2024-05-13 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2024-05-01 | Hochstufung | Craig Hallum | Hold → Buy |
| 2023-11-09 | Hochstufung | Stephens | Equal-Weight → Overweight |
| 2023-08-15 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2023-05-11 | Herabstufung | BTIG Research | Buy → Neutral |
| 2023-03-07 | Herabstufung | Stephens | Overweight → Equal-Weight |
| 2023-03-03 | Herabstufung | Craig Hallum | Buy → Hold |
| 2023-03-03 | Herabstufung | Raymond James | Strong Buy → Mkt Perform |
| 2022-04-25 | Eingeleitet | Stephens | Overweight |
| 2021-07-20 | Fortgesetzt | BTIG Research | Buy |
| 2021-06-03 | Eingeleitet | Goldman | Buy |
| 2021-02-26 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2020-10-30 | Bestätigt | H.C. Wainwright | Buy |
| 2020-10-08 | Bestätigt | H.C. Wainwright | Buy |
| 2020-10-02 | Bestätigt | H.C. Wainwright | Buy |
| 2020-08-05 | Bestätigt | H.C. Wainwright | Buy |
| 2020-06-26 | Eingeleitet | BTIG Research | Buy |
| 2020-06-19 | Bestätigt | H.C. Wainwright | Buy |
| 2019-10-01 | Fortgesetzt | Craig Hallum | Buy |
| 2019-05-09 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2019-02-15 | Eingeleitet | Jefferies | Buy |
| 2018-10-23 | Fortgesetzt | Raymond James | Strong Buy |
| 2018-09-18 | Bestätigt | H.C. Wainwright | Neutral |
| 2017-11-27 | Eingeleitet | H.C. Wainwright | Buy |
| 2016-06-14 | Bestätigt | Mizuho | Buy |
| 2015-09-29 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2015-09-25 | Eingeleitet | Craig Hallum | Buy |
| 2015-03-18 | Bestätigt | Mizuho | Buy |
Alle ansehen
Caredx Inc Aktie (CDNA) Neueste Nachrichten
CareDx to Report Q3 Earnings: Transplant Testing Growth in Focus - Zacks Investment Research
CareDx Reports AlloSure Kidney Data Showing Nearly Threefold Higher Risk of Adverse Transplant Outcomes - citybiz
CareDx links AlloSure Kidney to adverse graft outcomes - Mugglehead Investment Magazine
CareDx presents kidney transplant monitoring study results By Investing.com - Investing.com Australia
CareDx data links AlloSure Kidney test to graft outcome risk - StreetInsider
CareDx Announces New KOAR Data Linking Elevated AlloSure® Kidney to Nearly 3-Fold Higher Risk of Adverse Graft Outcomes in Patients with Borderline Rejection or TCMR at ASN Kidney Week 2026 - Business Wire
CareDx Faces First NavDx Quarter With Street Estimates Trailing Its Raised Outlook - Finviz
Caredx Inc stock hits 52-week high at 72.61 USD By Investing.com - Investing.com Canada
Pretax income of CareDx, Inc. – HAM:1K9 - TradingView
CareDx Inc (CDNA) Shares Surge 4.8% -- What GF Score of 64 Tells Investors - GuruFocus
CareDx Price Target Raised to $80.00/Share From $65.00 by Canaccord Genuity - Moomoo
CDNA Maintained by Canaccord Genuity -- Price Target Raised to $80 - GuruFocus
CareDx Inc (CDNA) Shares Fall 4.0% -- GF Value Says Still Overva - GuruFocus
CareDx, Inc. (CDNA) stock price, news, quote and history - Yahoo Finance Australia
CareDx, Inc (1K9.SG) stock price, news, quote and history - Yahoo Finance Australia
CareDx to Report Third Quarter 2026 Financial Results on October 29, 2026 - Business Wire
CareDx Inc (CDNA) Stock Up 3.7% but GF Value Says Overvalued -- GF Score: 64/100 - GuruFocus
CareDx (NASDAQ:CDNA) Stands Out for High Growth and Improving Fundamentals - ChartMill
Form 4 Caredx Inc For: 11 October By Investing.com - Investing.com South Africa
Form 4 Caredx Inc For: 11 October By Investing.com - Investing.com India
CareDx (CDNA) Stock Gets Fair Value Bump After Reimbursement And Analyst Target Changes - Yahoo Finance
A Look at CareDx Inc (CDNA) After 4.0% Gain -- GF Value $25.50 v - GuruFocus
Form 4 Caredx Inc For: 5 October By Investing.com - Investing.com South Africa
CareDx General Counsel Reports Withholding of Shares for RSU Tax Obligations - Kalkine Media
CareDx CEO John Walter Withholds 8,511 Shares for Tax on RSU Vesting - Kalkine Media
Stock vesting triggers 997-share tax withholding for CareDx (CDNA) counsel Jeffrey Adam Novack. - Stock Titan
CareDx CCO Jessica Meng Withholds 2,619 Shares for RSU Tax on October 1, 2026 - Kalkine Media
After 8,511 shares were withheld for taxes, CareDx (CDNA) CEO holds 644,937 shares directly. - Stock Titan
Tax withholding leaves CareDx (CDNA) CFO Keith Kennedy with 208,686 directly held shares. - Stock Titan
For stock-vesting taxes, CareDx (CDNA) withholds 2,619 shares from its chief commercial officer. - Stock Titan
A 588-share grant replaces cash pay for CareDx (CDNA) director Michael Goldberg. - Stock Titan
Immunogenomics Market Size, Share, Trends, and Growth Forecast, 2026-2033 | NGS and Personalized Medicine Drive Market Toward USD 9.82 Billion at 5.97% CAGR - GlobeNewswire Inc.
Biotech Stocks At 52-Week HighsCDNA, RCEL, AZTA, HNGE - RTTNews
CareDx, Inc (CDNA) stock price, news, quote and history - Yahoo Finance UK
Caredx Inc stock hits 52-week high at 65.53 USD - Investing.com
Caredx Inc stock hits 52-week high at 65.53 USD By Investing.com - Investing.com Canada
Caredx Inc stock hits 52-week high at 65.53 USD By Investing.com - Investing.com UK
Consumer Confidence Falls Amid Ongoing Geopolitical Tensions: 4 Picks - Zacks Investment Research
Consumer Confidence Falls Amid Ongoing Geopolitical Tensions: 4 Picks - es.tradingview.com
CareDx, Inc. (CDNA) Stock Price, News, Quote & History - Yahoo! Finance Canada
CareDx Refocused On Transplant Testing, And Wall Street Noticed - Finimize
CareDx, Inc. (CDNA) stock price, news, quote and history - Yahoo Finance Singapore
CareDx: I Was Wrong, But The Rally Has Outrun The Fundamentals (Rating Upgrade) - Seeking Alpha
CareDx (CDNA) Stock Jumps 13.0%: Will It Continue to Soar? - Yahoo Finance
CareDx Inc (CDNA) Stock Up 13.0% but GF Value Says Overvalued -- GF Score: 66/100 - gurufocus.com
CareDx +14% on Fresh $74 Analyst Price Target - Yahoo Finance
BTIG raises CareDx stock price target to $74 on transplant outlook - Investing.com
Zacks.com featured highlights include CareDx, Ciena, Celestica, Materion and MACOM Technology Solutions - Yahoo Finance
Medicare Lab Fee Changes Impact BillionToOne, CareDx Differently - Benzinga
A Look at CareDx Inc (CDNA) After 4.0% Gain -- GF Value $25.41 v - gurufocus.com
Finanzdaten der Caredx Inc-Aktie (CDNA)
Umsatz
Nettogewinn
Free Cashflow
ENV
Caredx Inc-Aktie (CDNA) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| PETER MAAG | Director |
Aug 14 '26 |
Proposed Sale |
45.30 |
7,000 |
317,113 |
0 |
| PETER MAAG | Director |
Aug 13 '26 |
Proposed Sale |
47.07 |
7,000 |
329,505 |
0 |
| PETER MAAG | Director |
Aug 12 '26 |
Proposed Sale |
46.89 |
7,000 |
328,238 |
0 |
| PETER MAAG | Director |
Aug 11 '26 |
Proposed Sale |
47.69 |
7,000 |
333,851 |
0 |
| PETER MAAG | Director |
Aug 10 '26 |
Proposed Sale |
47.66 |
6,902 |
328,949 |
0 |
| ARTHUR TORRES | Director |
Aug 10 '26 |
Proposed Sale |
47.73 |
4,200 |
200,475 |
0 |
| PETER MAAG | Director |
Aug 07 '26 |
Proposed Sale |
45.83 |
27,332 |
1,252,492 |
0 |
| GEORGE W BICKERSTAFF | Director |
Aug 05 '26 |
Proposed Sale |
46.28 |
20,000 |
925,700 |
0 |
| Bickerstaff George | Director |
Aug 05 '26 |
Sale |
46.28 |
20,000 |
925,700 |
134,061 |
| Novack Jeffrey Adam | Secretary and General Counsel |
Aug 05 '26 |
Sale |
46.26 |
2,688 |
124,349 |
106,075 |
6.20%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):